Introduction

Chronic myelogenous leukemia (CML) is a clonal proliferative disease originating from a pluripotential stem cell in which a 9:22 translocation, Philadelphia (Ph) chromosome, results in the production of BCR-ABL fusion protein that has constitutive tyrosine kinase activity and deregulates signal transduction pathways, thus causing leukemia. The natural course of CML is usually triphasic (chronic, accelerated and blast-crisis phases). The blast-crisis phase is refractory to standard chemotherapy. The introduction of imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, has caused rapid change in the treatment protocols for patients with CML. The great efficacy of imatinib in achieving a
The mechanism of imatinib resistance is classified into BCR-ABL dependency and non-dependency, and mutation of the BCR-ABL kinase domain is the most frequent. Structural changes in the BCR-ABL protein due to the mutation make it impossible to combine imatinib with BCR-ABL protein. It has been reported that leukemia cells with a mutation in the BCR-ABL gene had already existed before treatment with imatinib. In patients in whom an imatinib-resistant clone has not been generated, reduction of leukemia cells may lead to a decreased emergence of a resistant clone.
Monitoring of Minimal Residual Disease
The monitoring of minimal residual disease (MRD) by measuring the BCR-ABL chimera mRNA using the RT-PCR method is useful to assess the effect of treatment in patients with CCyR. In the IRIS study, 39% of patients treated with imatinib were estimated to have a 3 log reduction after 12 months of therapy (4). A 3 log or greater reduction in BCR-ABL levels after 12 months was associated with 98% progression-free survival at 42 months (2). Branford et al reported that it appears reasonable to conclude that even relatively small increases in the level of BCR-ABL transcript (>2 fold) are an indication that resistance may be developing and in such case, it is necessary to examine mutation of the BCR-ABL kinase domain (5).
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CML is performed. In their pilot study in newly diagnosed CML, the high-dose regimen compared to standard-dose imatinib, produced higher rates of CCyR and undetectable BCR-ABL transcript, and better progression-free survival (6).
Allogeneic Hematopoietic Stem cell Transplantation
In the pre-imatinib era, chronic phase patients under 50 years who had an HLA-matched sibling donor were recommended to have rapid allo-hematopoietic stem cell transplantation (HSCT). However, the role of allo-HSCT requires reassessment in the imatinib era (7). Early outcomes of imatinib therapy for patients with newly diagnosed chronic phase CML show a very high incidence of CCyR
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